LONDON — Haleon, a powerhouse in consumer health known for beloved brands like Sensodyne, parodontax, and Polident, has officially broken ground on its new Global Oral Health Innovation Centre in Weybridge, Surrey. This cutting-edge facility is poised to significantly amp up Haleon’s scientific prowess, fast-track new product development, and establish itself as a global hub for oral health research and breakthroughs.
Representatives from Haleon, Kier and the Department for Science, Innovation and Technology participating in the ceremony to mark the ground break.
The groundbreaking event, graced by UK Minister Baroness Jones, underscores Haleon’s ambitious vision to bring better everyday health to a billion more consumers by 2030. By bolstering its oral health R&D capabilities, Haleon aims to extend its reach globally. This new centre will serve as the nerve center for Haleon’s oral health innovation, fostering a dynamic environment for pioneering research, product development, commercial strategy, supply chain optimization, and cross-functional collaboration.
Equipped with the latest technology and drawing on global expertise, the facility will feature a state-of-the-art digital immersive room. This will enable real-time collaboration with Haleon’s manufacturing site in Levice, accelerating the pace of innovation and value creation.
At the heart of the centre, a central atrium is designed to be a vibrant hub for teamwork and co-creation. It will bring together leading minds to develop solutions that address pressing, unmet oral health needs for consumers worldwide.
Sustainability is a key design principle for the new centre, which has already secured a BREEAM® Outstanding rating for its design stage, recognizing its exceptional commitment to environmental performance.
Franck Riot, Chief R&D Officer at Haleon, expressed his enthusiasm: “We are thrilled to commence construction on our Global Oral Health Innovation Centre. This significant investment reflects our unwavering commitment to advancing science and innovation. This powerhouse for oral health research will enhance Haleon’s R&D capabilities and accelerate the development of groundbreaking solutions to meet the evolving oral health needs of consumers globally.”
The Chancellor of the Exchequer, Rachel Reeves MP, commented on the milestone: “This exciting development is a further testament to the strength of the UK’s life sciences sector, a cornerstone of our Industrial Strategy. Under this government, Britain is open for business, and through our Plan for Change, we are driving investment, creating jobs, and boosting economic prosperity.”
UK Minister for Technology, Baroness Jones, added: “Haleon’s new centre will position the UK at the forefront of innovation, aiming to improve oral health for everyone. We recognize the critical link between oral health and overall well-being, particularly for children’s development. This substantial investment is clear evidence that the UK’s world-class life sciences sector is the ideal environment for businesses seeking growth and looking to drive transformative healthcare ideas. Harnessing these strengths will be crucial for achieving the long-term economic growth outlined in our Plan for Change.”
Jayant Singh, Global Category Lead for Oral Health at Haleon, highlighted the centre’s impact: “With oral diseases affecting nearly half the world’s population, this project marks a significant stride in our mission to empower millions worldwide with better everyday health. This centre will be instrumental in maximizing the potential of science and innovation across our entire oral health portfolio.”
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, dedicated to delivering better everyday health with humanity. The company’s comprehensive product portfolio spans Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon’s trusted and science-backed brands, including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren, are built on a foundation of innovation and a deep understanding of consumer needs.
View source version on businesswire.com:
Media Contacts
Philippa Keir
[email protected]
+44(0)7969271455
Source: Haleon
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/4025.html
